Project documents | Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] | Guidance | NICE

Documents

Documents created during the development process.

Draft guidance

Draft guidance
Equality impact assessment (downloadable version) (PDF 121 KB)

Published:

12 June 2025
Public committee slides (PDF 968 KB)

Published:

12 June 2025
Draft consultation document (downloadable version) (PDF 260 KB)

Published:

12 June 2025
Draft consultation document (online commenting)
Committee papers - ACM1 (PDF 7.09 MB)

Published:

24 June 2025

Declaration of interests

Register of interests (PDF 106 KB)

Published:

09 April 2025

Invitation to participate

Equality impact assessment (Scoping) (PDF 128 KB)

Published:

11 March 2024
Final stakeholder list (PDF 198 KB)

Published:

11 March 2024
Final scope (PDF 211 KB)

Published:

11 March 2024
Draft scope and provisional stakeholder list comments table (post-referral) (PDF 235 KB)

Published:

11 March 2024

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6212

Draft matrix post referral (PDF 198 KB)

Published:

15 January 2024
Draft scope post referral (PDF 222 KB)

Published:

15 January 2024